2022
DOI: 10.1016/j.nano.2022.102592
|View full text |Cite
|
Sign up to set email alerts
|

Nano-drug delivery system with enhanced tumour penetration and layered anti-tumour efficacy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 35 publications
0
3
0
Order By: Relevance
“…In accordance with eqn (1) and (2), the DOX loading capacity (LC) and entrapment efficiency (EE) of PC-LDHs and ZIF-8@LDHs core–shell structures were successfully calculated. 34 Table 1 demonstrated that the LC and EE of ZIF-8@LDHs core–shell structures were marginally lower than those of PC-LDHs while the aqueous concentration of DOX was 1 mg mL −1 and weight ratio of carriers to DOX was 4 : 1. This agrees with previous thermogravimetric results.…”
Section: Resultsmentioning
confidence: 99%
“…In accordance with eqn (1) and (2), the DOX loading capacity (LC) and entrapment efficiency (EE) of PC-LDHs and ZIF-8@LDHs core–shell structures were successfully calculated. 34 Table 1 demonstrated that the LC and EE of ZIF-8@LDHs core–shell structures were marginally lower than those of PC-LDHs while the aqueous concentration of DOX was 1 mg mL −1 and weight ratio of carriers to DOX was 4 : 1. This agrees with previous thermogravimetric results.…”
Section: Resultsmentioning
confidence: 99%
“…[168][169][170] Compared to conventional drug delivery methods, nanomedicine primarily emphasizes targeted drug delivery, supporting effective treatments for various infectious diseases, cancers, diabetes, and neurodegenerative disorders such as Alzheimer's disease. 171,172 Several successful nanocarriers, including dendrimers, nanoparticles, liposomes, and carbon nanotubes, have been commercialized. These carriers achieve precise targeting and rapid accumulation at the site of action without reliance on any biological system intervention.…”
Section: Latest Research Developments and Case Studiesmentioning
confidence: 99%
“…Nanoparticles with different surface properties can be prepared by adjusting the ratio of different components in the carrier material as well as the ratio of drug to carrier while optimizing the drug loading and encapsulation rate, with a higher loading capacity favoring a better therapeutic effect. Passive targeting is achieved by modulating the size and surface properties of nanoparticles to promote their selective accumulation in tumors through the EPR effect [22]. Active targeting can be achieved by modifying nanomaterials with high-a nity ligands, such as HA [23], folic acid [24], and mannose [25].…”
Section: Introductionmentioning
confidence: 99%